The company expects this marketing approval to enable it to rapidly expand its operations not only in Saudi Arabia, the largest pharma market in GCC region, but other GCC and MENA countries as well The marketing authorisation from Saudi Arabia comes as an evident
The company expects this approval for Meropenem 500mg, Meropenem 1000mg, Meropenem 2000mg, Oxaliplatin 5mg/ml, Paclitaxil 6mg/ml, Cisplatin 1mg/ml, Imipenem/Cilastatin 500mg/500mg of its Carbapenem & Oncology production facilities in Baddi to pave the way for GMP certifications from European Medicines Agency and other Pharmaceutical Inspection
Join 2M+ industry professionals with MedgateToday - curated insights, delivered daily.
